Cargando…
Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia
BACKGROUND: After the approval of dutastride for androgenic alopecia (AGA) in 2009, Korean authority required a post-marketing surveillance to obtain further data on its safety profile. OBJECTIVE: The objective was to monitor adverse events (AEs) of dutasteride 0.5 mg in Korean AGA male patients in...
Autores principales: | Choi, Gwang Seong, Kim, Joon Hyung, Oh, Shin-Young, Park, Jung-Min, Hong, Ji-Soo, Lee, Yil-Seob, Lee, Won-Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Dermatological Association; The Korean Society for Investigative Dermatology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969473/ https://www.ncbi.nlm.nih.gov/pubmed/27489426 http://dx.doi.org/10.5021/ad.2016.28.4.444 |
Ejemplares similares
-
Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia
por: Saceda-Corralo, David, et al.
Publicado: (2017) -
Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
por: Tsai, Tsen‐Fang, et al.
Publicado: (2018) -
Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia
por: Rhie, Arang, et al.
Publicado: (2019) -
Evaluation of hair regrowth after minoxidil and dutasteride tattooing in men with androgenetic alopecia
por: Ragi, Sara D., et al.
Publicado: (2023) -
Characteristics of Androgenetic Alopecia in Asian
por: Lee, Won-Soo, et al.
Publicado: (2012)